Clinical Data
| Case . | Sex/Age . | Status/mo After Diagnosis . | Diagnosis . | Immunophenotype . | Organ Involvement-150 . | Treatment/Response . | Survival (mo) . |
|---|---|---|---|---|---|---|---|
| 1 | M/49 | P | aCML | BM, PB, spleen, LN | HU; HU + IFN/NR | 6-151 | |
| 2 | M/13 | P | RAEB-t | BM (18%), PB (25%), LN, liver | AEIM/NR | 17-151 | |
| R/11 | AML | CD34+, CD33+, CD13+, CD117+, TdT+, CD14−, CD15− | BM (40%), PB (34%), liver, spleen | AEMAmC/NR | |||
| 3 | M/4 | P | AML-M0 | CD34+, CD33+, CD13−, TdT+, CD14−, CD15− | BM (93%), PB (13%) | EORTC-AML 58872/NR | 2-151 |
| 4 | M/5 | P | ALL-L2 | CD34+, CD10+, CD3+, CD20+, TdT+, CD13+, CD33+ | BM (96%), PB (37%) | EORTC CLCG-ALL 58881/CR | 24 |
| 5 | M/1 | P | AML | CD34+, CD32+, CD13+, CD116+, CD4+, CD56+, CD38+, HLH-DR+ | BM (77%), PB (70%) spleen, liver | EORTC CLCG-AML 58921/NR | 5 |
| 6 | F/17 | P | ALL-L1 | CD10+, CD19+, HLH-DR+, TdT+, slg+, clg:+ | BM (98%), PB (79%), LN | ALL BMFT/CR | 29-151 |
| R/22 | CVAD, AE, TBI&C, ABMT/CR | ||||||
| R/28 | VIMA, BuM, APBSCT/NR | ||||||
| 7 | M/70 | P | MZBL | slgM+, CD19+, CD20+, CD22+, FMC7+, HLA-DR+, CD24+, CD5−, CD10−, CD23−, CD15−, CD103− | BM (49%), PB (27%), LN, spleen | Chlorambucil | 10 |
| Case . | Sex/Age . | Status/mo After Diagnosis . | Diagnosis . | Immunophenotype . | Organ Involvement-150 . | Treatment/Response . | Survival (mo) . |
|---|---|---|---|---|---|---|---|
| 1 | M/49 | P | aCML | BM, PB, spleen, LN | HU; HU + IFN/NR | 6-151 | |
| 2 | M/13 | P | RAEB-t | BM (18%), PB (25%), LN, liver | AEIM/NR | 17-151 | |
| R/11 | AML | CD34+, CD33+, CD13+, CD117+, TdT+, CD14−, CD15− | BM (40%), PB (34%), liver, spleen | AEMAmC/NR | |||
| 3 | M/4 | P | AML-M0 | CD34+, CD33+, CD13−, TdT+, CD14−, CD15− | BM (93%), PB (13%) | EORTC-AML 58872/NR | 2-151 |
| 4 | M/5 | P | ALL-L2 | CD34+, CD10+, CD3+, CD20+, TdT+, CD13+, CD33+ | BM (96%), PB (37%) | EORTC CLCG-ALL 58881/CR | 24 |
| 5 | M/1 | P | AML | CD34+, CD32+, CD13+, CD116+, CD4+, CD56+, CD38+, HLH-DR+ | BM (77%), PB (70%) spleen, liver | EORTC CLCG-AML 58921/NR | 5 |
| 6 | F/17 | P | ALL-L1 | CD10+, CD19+, HLH-DR+, TdT+, slg+, clg:+ | BM (98%), PB (79%), LN | ALL BMFT/CR | 29-151 |
| R/22 | CVAD, AE, TBI&C, ABMT/CR | ||||||
| R/28 | VIMA, BuM, APBSCT/NR | ||||||
| 7 | M/70 | P | MZBL | slgM+, CD19+, CD20+, CD22+, FMC7+, HLA-DR+, CD24+, CD5−, CD10−, CD23−, CD15−, CD103− | BM (49%), PB (27%), LN, spleen | Chlorambucil | 10 |
Abbreviations: P, primary diagnosis; aCML, atypical chronic myeloid leukemia; BM, bone marrow; PB, peripheral blood; LN, lymph node; HU, hydroxyurea; IFN, interferon; NR, no response; RAEB-t, refractory anemia with excess of blasts in transformation; AEIM, cytosine-arabinoside, etoposide, idarubicin, mitoxantrone; R, relapse; AML, acute myeloid leukemia; AEMAmC, cytosine-arabinoside, etoposide, mitoxantrone, m-Amsa, cyclosporine; EORTC-AML 58872, cytosine-arabinoside, mitoxantrone, etoposide; ALL, acute lymphoblastic leukemia; EORTC CLCG-ALL 58881, prednisone, vincristine, daunorubicine, L-asparaginase, cyclophosphamide, mercaptopurine, cytosine-arabinoside, methotrexate, dexamethasone, doxorubicine, 6-thioguanine; CR, complete remission; EORTC CLCG-AML 58921, cytosine-arabinoside, mitoxantrone, etoposide; BMFT, daunorubicin, vincristine, prednisone, L-asparaginase, cyclophosphamide, cytosine-arabinoside, 6-mercaptopurine, teniposide; CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; AE, cytosine-arabinoside, etoposide; TBI&C, total body irradiation and cyclophosphamide; ABMT, allogeneic bone marrow transplantation; VIMA, etoposide, ifosfamide, mitoxantrone, cytosine-arabinoside; BuM, busulfane, melphalan; APBSCT, allogeneic peripheral blood stem cell transplantation; MZBCL, marginal zone B-cell lymphoma.
In brackets % of blasts in case 2-6, or malignant lymphocytes in case 7.
Died.